Molecular Partners (MOLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on the stock and has a $9.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jonathan Chang has given his Buy rating due to a combination of factors that highlight Molecular Partners’ strategic advancements and promising pipeline developments. The company has made significant progress with its Radio-DARPin Therapy (RDT) programs, particularly with MP0712, which is now moving directly into a Phase I dose escalation study following discussions with the FDA. This advancement underscores the potential of MP0712 as a radiopharmaceutical candidate in the DLL3 space, supported by a reliable radioisotope supply from its partnership with Orano Med.
Additionally, Molecular Partners is on track with its non-RDT programs, including the upcoming data presentation for MP0533 at the European Hematology Association Congress. The extended follow-up data from relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients further bolster the company’s pipeline prospects. These developments, along with the planned submission of an IND application for MP0712 and the initiation of its Phase I study, contribute to a positive outlook for the company’s stock.
In another report released on May 14, LifeSci Capital also maintained a Buy rating on the stock with a $12.00 price target.